Pharmacological overtreatment in epilepsy: Mechanisms and management

Epilepsy Research

Volumn 52, Issue 1, 2002, Pages 3-14

  Schmidt, Dieter ^a   Elger, Christian ^b   Holmes, Gregory L ^c  

^a Epilepsy Research Group   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antiepileptic drug; Drug resistance; Epilepsy; Maximum tolerated dose; Overtreatment; Polytherapy; Prevention

Indexed keywords

ANTICONVULSIVE AGENT;

CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG USE; EPILEPSY; FOCAL EPILEPSY; HUMAN; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; TITRIMETRY;

ANTICONVULSANTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; RISK FACTORS; TREATMENT FAILURE;

EID: 0036848615     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(02)00180-8     Document Type: Conference Paper

References (40)

1. Albright P., Bruni J. Reduction of polypharmacy in epileptic patients. Arch. Neurol. 42:1985;797-799.
2. Berg A.T., Shinnar S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology. 44:1994;601-608.
3. Besag F.M.C., Berry D.J., Pool F., et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia. 39:1998;183-187.
4. Biton V., Edwards K.R., Montouris G.D., Sackellares J.C., Harden C.L., Kamin M. Topiramate titration and tolerability. Ann. Pharmacother. 35:2001;173-179.
5. Borowicz K.K., Kleinrok Z., Czuczwar S.J. The AMPA/kainate receptor antagonist, LY 300164, increases the anticonvulsant effects of diazepam. Naunyn-Schmiedeb. Arch. Pharmacol. 361:2000;629-635.
6. Borowicz K.K., Czuczwar S.J. Effect of SIB 1893 on the protective action of carbamazepine and valproate in amygdala-kindled rats. Epileptologia. 10:(Suppl. 1):2002;73.
7. Camfield P., Camfield C., Stephanie Smith, Dooley J., Smith E. Long-term outcome is unchanged by antiepileptic drug treatment after a first seizure: a 15-year follow up from a randomized trial in childhood. Epilepsia. 43:2002;662-663.
8. Claes L., Del-Favero J., Ceulemans B., Lagae L., Van Broeckhoven C., De Jonghe P. De novo mutations in the sodium-channel gene scn1a cause severe myoclonic epilepsy of infancy. Am. J. Hum. Genet. 68:2001;1327-1332.
9. Corda D., Gelisse P., Genton P., Dravet C., Baldy-Moulinier M. Incidence of drug-induced aggravation in benign epilepsy with centrotemporal spikes. Epilepsia. 42:2001;749-754.
10. Deckers C.L., Czuczwar S.J., Hekster Y.A., Keyser A., Kubova H., Meinardi H., Patsalos P.N., Renier W.O., Van Rijn C.M. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 41:2000;1364-1374.
11. De Santis A., Villani R., Sinisi M., Stocchetti N., Perucca E. Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia. 43:2002;175-182.
12. Donat J.F., Wright F.S. Episodic symptoms mistaken for seizures in the neurologically impaired child. Neurology. 40:1990;156-157.
13. First Seizure Trial Group . Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. Neurology. 43:1993;478-483.
14. Fischbacher E. Effect of reduction of anticonvulsants on wellbeing. Br. Med. J. (Clin. Res. Ed.). 285:1982;423-424.
15. Guerrini R., Belmonte A., Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia. 39:(Suppl. 3):1998;S2-S10. Guerrini et al. 2002 EPI.
16. Holmes L.B., Harvey E.A., Coull B.A., et al. The teratogenicity of anticonvulsant drugs. N. Engl. J. Med. 344:2001;1132-1138.
17. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 342:2000;314-319.
18. Kwan P., Brodie M.J. Effectiveness of first antiepileptic drug. Epilepsia. 42:2001;1255-1260.
19. Löscher W., Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 17:1994;95-134.
20. Löscher, W., Schmidt, D., 2002. New horizons in the development of antiepileptic drugs. Epilepsy Res. 50, 3-16.
21. Musicco M., Beghi E., Solari A., Viani F. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First Seizure Trial Group (FIRST Group). Neurology. 49:1997;991-998.
22. Medical Research Council Antiepileptic Drug Withdrawal Study Group . Randomised study of antiepileptic drug withdrawal in patients in remission. Lancet. 337:1991;1175-1180.
23. Pellock J.M., Hunt P.A. A decade of modern epilepsy therapy in institutionalized mentally retarded patients. Epilepsy Res. 25:1996;263-268.
24. Perucca E., Beghi E., Dulac O., et al. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res. 41:2000;107-139.
25. Privitera M.D., Brodie M., Nieto W., et al. Topiramate vs investigator choice of carbamazepine or valproate as monotherapy in newly diagnosed epilepsy. Epilepsia. 41:(Suppl. 7):2000;93-94.
26. Schmidt D. Overtreatment in epilepsy and how to avoid it. Schmidt D., Schachter S.C., Epilepsy. Problem Solving in Clinical Practice. 2000;231-240 Martin Dunitz, London.
27. Schmidt D. Reduction of two-drug therapy in intractable epilepsy. Epilepsia. 24:1983;368-376.
28. Schmidt D., Haenel F. Therapeutic plasma levels of phenytoin, phenobarbital and carbamazepine: individual variation in relation to seizure type. Neurology. 34:1984;1252-1253.
29. Schmidt, D., 2002. The clinical impact of new antiepileptic drugs after a decade of use in epilepsy. Epilepsy Res. 50, 21-32.
30. Schmidt D., Gram L. Monotherapy versus polytherapy in epilepsy. A reappraisal. CNS Drugs. 3:1995;194-208.
31. Schmidt, D., Rogawski, M.A., 2002. New strategies for the identification of drugs to prevent the development or progression of epilepsy. Epilepsy Res. 50, 71-78.
32. Schiller Y., Cascino G.D., So E.L., Walsh W.R. Discontinuation of antiepileptic drugs after successful epilepsy surgery. Neurology. 54:2000;346-349.
33. Shank P.R., Gardocki J.F., Vaught J.L., et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia. 35:1994;450-460.
34. Shorvon S.D., Reynolds E.H. Unnecessary polypharmacy for epilepsy. Br. Med. J. 1:1977;1635-1637.
35. Specchio L.M., Tramacere L., La Neve A., Beghi E. Discontinuing antiepileptic drugs in patients who are seizure free on monotherapy. J. Neurol. Neurosurg. Psychiatry. 72:2002;22-25.
36. Sugawara, T., Mazaki-Miyazaki, E., Fukushima, K., Shimomura, J., Fujiwara, T., Hamano, S., Inoue, Y., Yamakawa, K., 2002. Frequent mutations of SCN1A in severe myoclonic epilepsy in infancy. Neurology 58, 1122-1124.
37. Temkin N.R. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia. 42:2001;515-524.
38. Temkin N.R., Jarell A.D., Anderson G.D. Antiepileptogenic agents: how close are we? Drugs. 61:2001;1045-1055.
39. Theodore W.H., Porter R.J. Removal of sedative-hypnotic antiepileptic drugs from the regimens of patients with intractable epilepsy. Ann. Neurol. 13:1983;320-324.
40. Tiffin P.A., Perini A.F. The use of antiepileptic drugs in learning disabled people with epilepsy: an audit of adult in-patients in a treatment and continuing care service. Seizure. 10:2001;500-504.